Angela Hansen

Winsantor, Inc.

$8,652,875

Attributed

$9,002,620

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY2014–22

$2.5M$1.9M$1.3M$625K$0

'14

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$9,002,620 · 4

By mechanism

R44$7,332,903 · 2

SB1$970,226 · 1

R41$699,491 · 1

Top collaborators

Nigel A Calcutt1 shared

Most similar at Winsantor, Inc.

Same institution · by research overlap

Andrew Mizisin$2,779,181

Others in their field

Top investigators on “In Vivo”

David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
Dennis R. Burton · Scripps Research Institute$212,708,174
Mark S Klempner · Tufts Medical Center$128,021,180
Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200

Research focus

In VivoTopical ApplicationFda ApprovedDoseSafetyNon-Insulin-Dependent Diabetes MellitusPirenzepineClinical TrialsRodent ModelNeuropathyPreventPainDiabetes MellitusPharmaceutical PreparationsIn VitroBaseFundingUnited States National Institutes Of HealthDiabetic NeuropathiesPreclinical StudySmall Business Innovation Research GrantSuccessFormulationAmerican